^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Alymsys (bevacizumab-maly) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/13/2022
Excerpt:
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of...Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
Secondary therapy:
paclitaxel + pegylated liposomal doxorubicin; topotecan
Source:
Title:
European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer
Published date:
03/31/2021
Excerpt:
...The European Commission (EC) has approved mAbxience's MB02 biosimilar to Avastin® (Bevacizumab), in Europe....MB02, to be commercialized as Alymsys® and Oyavas®...MB02 is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
